930 reports of this reaction
2.2% of all HYDROXYUREA reports
#9 most reported adverse reaction
HAEMOGLOBIN DECREASED is the #9 most commonly reported adverse reaction for HYDROXYUREA, manufactured by H2-Pharma LLC. There are 930 FDA adverse event reports linking HYDROXYUREA to HAEMOGLOBIN DECREASED. This represents approximately 2.2% of all 42,593 adverse event reports for this drug.
Patients taking HYDROXYUREA who experience haemoglobin decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOGLOBIN DECREASED is a less commonly reported adverse event for HYDROXYUREA, but still significant enough to appear in the safety profile.
In addition to haemoglobin decreased, the following adverse reactions have been reported for HYDROXYUREA:
The following drugs have also been linked to haemoglobin decreased in FDA adverse event reports:
HAEMOGLOBIN DECREASED has been reported as an adverse event in 930 FDA reports for HYDROXYUREA. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOGLOBIN DECREASED accounts for approximately 2.2% of all adverse event reports for HYDROXYUREA, making it a notable side effect.
If you experience haemoglobin decreased while taking HYDROXYUREA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.